Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support.

Authors:
Scot J Matkovich
Scot J Matkovich
Center for Pharmacogenomics
Keith A Youker
Keith A Youker
From the Methodist Diabetes and Metabolism Institute
Abhinav Diwan
Abhinav Diwan
Washington University School of Medicine
United States
William H Eschenbacher
William H Eschenbacher
Washington University School of Medicine
United States
Lisa E Dorn
Lisa E Dorn
Washington University
United States
Mark A Watson
Mark A Watson
Washington University School of Medicine
United States

Circulation 2009 Mar 23;119(9):1263-71. Epub 2009 Feb 23.

Center for Pharmacogenomics, Washington University, St Louis, MO 63110, USA.

Background: Much has been learned about transcriptional control of cardiac gene expression in clinical and experimental congestive heart failure (CHF), but less is known about dynamic regulation of microRNAs (miRs) in CHF and during CHF treatment. We performed comprehensive microarray profiling of miRs and messenger RNAs (mRNAs) in myocardial specimens from human CHF with (n=10) or without (n=17) biomechanical support from left ventricular assist devices in comparison to nonfailing hearts (n=11).

Methods And Results: Twenty-eight miRs were upregulated >2.0-fold (P<0.001) in CHF, with nearly complete normalization of the heart failure miR signature by left ventricular assist device treatment. In contrast, of 444 mRNAs that were altered by >1.3-fold in failing hearts, only 29 mRNAs normalized by as much as 25% in post-left ventricular assist device hearts. Unsupervised hierarchical clustering of upregulated miRs and mRNAs with nearest centroid analysis and leave-1-out cross-validation revealed that combining the miR and mRNA signatures increased the ability of RNA profiling to serve as a clinical biomarker of diagnostic group and functional class.

Conclusions: These results show that miRs are more sensitive than mRNAs to the acute functional status of end-stage heart failure, consistent with important functions for regulated miRs in the myocardial response to stress. Combined miR and mRNA profiling may have superior potential as a diagnostic and prognostic test in end-stage cardiomyopathy.

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.108.813576DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749457PMC
March 2009
8 Reads

Publication Analysis

Top Keywords

heart failure
8
ventricular assist
8
biomechanical support
8
mir mrna
8
mirs
6
hearts unsupervised
4
hierarchical clustering
4
unsupervised hierarchical
4
device hearts
4
25% post-left
4
post-left ventricular
4
assist device
4
clustering upregulated
4
upregulated mirs
4
centroid analysis
4
analysis leave-1-out
4
leave-1-out cross-validation
4
nearest centroid
4
test end-stage
4
mirs mrnas
4

Altmetric Statistics

Similar Publications

A micro-ribonucleic acid signature associated with recovery from assist device support in 2 groups of patients with severe heart failure.

J Am Coll Cardiol 2011 Nov;58(22):2270-8

Heart and Vascular Institute, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA.

Objectives: This study was conducted to test the hypothesis that cardiac micro-ribonucleic acid (miR) profiling in severe heart failure patients at the time of ventricular assist device (VAD) placement would differentiate those who remained VAD-dependent from those with subsequent left ventricular (LV) recovery.

Background: The relationship of myocardial miR expression to ventricular recovery is unknown.

Methods: We studied 28 patients with nonischemic cardiomyopathy requiring VAD support consisting of test and validation cohorts from 2 institutions: 14 with subsequent LV recovery and VAD removal and 14 clinically matched VAD-dependent patients. Read More

View Article
November 2011

Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support.

Circulation 2014 Mar 15;129(9):1009-21. Epub 2014 Jan 15.

Department of Developmental Biology (K.-C.Y., J.M.N.) and Center for Cardiovascular Research, Division of Cardiology, Department of Internal Medicine (K.A.Y., A.Y.P., V.K.T., G.A.E., D.L.M.), Washington University Medical School, St. Louis, MO; Division of Cardiothoracic Surgery, New York Presbyterian Hospital, Columbia University College of Physicians and Surgeons, New York, NY (I.G.); and Department of Surgery, University of Maryland School of Medicine, Baltimore (F.H.C.). Dr Yang's current affiliation is the Department of Pharmacology, National Taiwan University School of Medicine, Taipei, Taiwan.

Background: Microarrays have been used extensively to profile transcriptome remodeling in failing human heart, although the genomic coverage provided is limited and fails to provide a detailed picture of the myocardial transcriptome landscape. Here, we describe sequencing-based transcriptome profiling, providing comprehensive analysis of myocardial mRNA, microRNA (miRNA), and long noncoding RNA (lncRNA) expression in failing human heart before and after mechanical support with a left ventricular (LV) assist device (LVAD).

Methods And Results: Deep sequencing of RNA isolated from paired nonischemic (NICM; n=8) and ischemic (ICM; n=8) human failing LV samples collected before and after LVAD and from nonfailing human LV (n=8) was conducted. Read More

View Article
March 2014

Mixed messages: transcription patterns in failing and recovering human myocardium.

Circ Res 2005 Mar 17;96(5):592-9. Epub 2005 Feb 17.

Cardiovascular Research Center, Cardiovascular Research Institute, University of Pennsylvania School of Medicine, Temple University School of Medicine, Philadelphia, Pa 19104-6160, USA.

In previous studies, mechanical support of medically refractory hearts with a left ventricular assist device (LVAD) has induced regression of many morphological and functional abnormalities characteristic of failing human hearts. To identify transcriptional adaptations in failing and LVAD-supported hearts, we performed a comprehensive transcription analysis using the Affymetrix microarray platform and 199 human myocardial samples from nonfailing, failing, and LVAD-supported human hearts. We also used a novel analytical strategy that defines patterns of interest based on multiple intergroup comparisons. Read More

View Article
March 2005

Differential Cardiac MicroRNA Expression Predicts the Clinical Course in Human Enterovirus Cardiomyopathy.

Circ Heart Fail 2015 May 11;8(3):605-18. Epub 2015 Mar 11.

From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund).

Background: Investigation of disease pathogenesis confined to protein-coding regions of the genome may be incomplete because many noncoding variants are associated with disease. We aimed to identify novel predictive markers for the course of enterovirus (CVB3) cardiomyopathy by screening for noncoding elements influencing the grossly different antiviral capacity of individual patients.

Methods And Results: Transcriptome mapping of CVB3 cardiomyopathy patients revealed distinctive cardiac microRNA (miR) patterns associated with spontaneous virus clearance and recovery (CVB3-ELIM) versus virus persistence and progressive clinical deterioration (CVB3-PERS). Read More

View Article
May 2015